The stock's rise snapped a four-day losing streak.

Amid increasing economic tensions with the United States, China recently announced that it would ban Illumina, a U.S.-based company and the ...

Cramer looks at Illumina, Archer Aviation, NANO Nuclear Energy, Steris, Sixth Street Specialty Lending, Lam Research and ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

RBC Capital lowered the firm’s price target on Illumina (ILMN) to $128 from $247 but keeps an Outperform rating on the shares. The company’s ...

In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...

Today, Benzinga's options scanner identified 8 options transactions for Illumina. This is an unusual occurrence. The ...

Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...

What a brutal six months it’s been for Illumina. The stock has dropped 30.9% and now trades at $84.65, rattling many ...

Illumina has been barred from exporting its DNA sequencers to China, which closed | Illumina has been barred from exporting ...

Illumina stock skidded Tuesday after China signaled it would ban the company from importing its gene-mapping products.